Professor Chris Snyder and his colleague at the Market Shaping Accelerator, Sarrin Chethik, suggest strategies and policy changes to incentivize research into the hidden benefits of familiar drugs that have shown potential for new treatments.r
Read their Op-Ed here in the Wall Street Journal